FLT3 and acute myeloid leukemia: Similar phase III studies of quizartinib vs. placebo (NCT02668653) and crenolanib vs. midostaurin (NCT03258931) in combination with chemotherapy are also ongoing, aiming to provide evidence on the most efficacious FLT3 TKI in newly diagnosed FLT3-mutant AML.